A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

• Status: Completed
• Trial end date: 2011-07-27
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore the efficacy and safety of multiple, escalating doses of ASP015K when compared to placebo in subjects with moderate to severe plaque psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Peficitinib

Criteria

Inclusion Criteria:

• Subject has moderate to severe plaque psoriasis for 6 months or longer with at least 10% Body Surface Area (BSA) affected

• Subject must be a candidate for phototherapy and/or systemic therapy

Exclusion Criteria:

• Subject has non-plaque psoriasis or drug-induced psoriasis

• Subject is on systemic psoriasis therapy within 56 days or 5 half-lives, whichever is longer, prior to first dose of study drug

• Subject has a positive TB skin test within 3 months of screening or at screening

• Subject has an abnormal chest x-ray